T. Rowe Price Associates’s NervGen Pharma NGEN Stock Holding History

T. Rowe Price Associates’s Portfolio NGEN Stock Details NGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$59K	Buy	+15,504	New	+$67.2K	﹤0.01%	3061

Other funds holding NGEN

PFG Investments Woodbury, New York $2.15B AUM 25.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

IWC

Integrated Wealth Concepts Waltham, Massachusetts $12.5B AUM 18.49% 1-Year Est. Return

VFIC

Valley Forge Investment Consultants Audubon, Pennsylvania $334M AUM 17.84% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

T. Rowe Price Associates's NGEN Position: Q1 2026 in Review

T. Rowe Price Associates opened a new position in NervGen Pharma (NGEN) in Q1 2026: 15,504 shares worth $59K. The stake represents ﹤0.01% of the portfolio and ranks #3061 among its holdings.

45 funds tracked by Wall St. Rank hold NGEN as of Q1 2026.

T. Rowe Price Associates held 15,504 shares of NervGen Pharma worth $59K as of Q1 2026.
NervGen Pharma was a new T. Rowe Price Associates position in Q1 2026.
NervGen Pharma made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3061 holding.
45 funds tracked by Wall St. Rank held NervGen Pharma as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.